Related Experiment Videos
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
E L Anderson1, D J Kennedy, K M Geldmacher
1Department of Pediatric, St. Louis University School of Medicine, Missouri, USA.
Insights
A new seven-valent pneumococcal conjugate vaccine is safe and effective in infants. It generates strong immune responses and lasting immunologic memory against pneumococcal disease.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Immunology
Background:
- Pneumococcal infections pose a significant threat to infant health.
- Developing effective vaccines for young infants is crucial for disease prevention.
Purpose of the Study:
- To assess the safety and immunogenicity of a novel seven-valent pneumococcal conjugate vaccine in infants.
- To evaluate the development of immunologic memory following vaccination.
Main Methods:
- Healthy 2-month-old infants received the investigational pneumococcal conjugate vaccine at 2, 4, and 6 months.
- A control group received a licensed pneumococcal polysaccharide vaccine.
- Immunogenicity and safety were monitored throughout the study.
Main Results:
- The investigational vaccine was well-tolerated in infants.
- High antibody levels against all seven serotypes were observed after vaccination.
- Infants vaccinated with the conjugate vaccine showed robust immunologic memory upon booster dose.
Conclusions:
- The seven-valent pneumococcal conjugate vaccine is safe and highly immunogenic in young infants.
- The vaccine effectively primes the immune system, establishing long-term protection.
- This conjugate vaccine offers a promising strategy for preventing pneumococcal disease in infants.
Objective:
To evaluate the safety, immunogenicity, and immunologic memory in young infants of a seven-valent (6B, 14, 19F, 23F, 18C, 4, 9V) pneumococcal vaccine conjugated to the outer membrane protein complex of Neisseria meningitidis. VACCINEES: Healthy 2-month-old infants 12- to 15-month-old control infants were recruited from participating private practices.
Methods:
Infants (n = 25) were vaccinated at 2, 4, and 6 months of age with the conjugated pneumococcal vaccine, followed by a single dose of licensed pneumococcal polysaccharide vaccine (n = 20) at 12 to 15 months of age. Thirteen infants who had not received the investigational pneumococcal conjugate vaccine served as control subjects and were given a single dose of the licensed pneumococcal polysaccharide vaccine at 12 to 15 months of age.
Results:
The investigational pneumococcal conjugate vaccine was well tolerated by infants. The vaccine was highly immunogenic in young infants, with significant increases in antibody to all seven serotypes after either two or three injections. At 12 to 15 months of age, infants who had been primed with the investigational pneumococcal conjugate vaccine had a brisk immunologic response to the booster injection of the licensed pneumococcal polysaccharide vaccine. Control infants, who received a single primary injection of the licensed pneumococcal polysaccharide vaccine, had negligible immunologic responses to four of the seven serotypes and low responses to the other three types.
Conclusion:
The investigational seven-valent pneumococcal conjugate vaccine administered to young infants was well tolerated and highly immunogenic and provided immunologic memory to an injection of the licensed pneumococcal polysaccharide vaccine.